Feasibility of a transmucosal sublingual fentanyl tablet as a procedural pain treatment in colonoscopy patients: a prospective placebo-controlled randomized study
- PMID: 33262414
- PMCID: PMC7708418
- DOI: 10.1038/s41598-020-78002-0
Feasibility of a transmucosal sublingual fentanyl tablet as a procedural pain treatment in colonoscopy patients: a prospective placebo-controlled randomized study
Abstract
Since patients often experience pain and unpleasantness during a colonoscopy, the present study aimed to evaluate the efficacy and safety of sublingually administered fentanyl tablets for pain treatment. Furthermore, since the use of intravenous drugs significantly increases colonoscopy costs, sublingual tablets could be a cost-effective alternative to intravenous sedation. We conducted a prospective placebo-controlled randomized study of 158 patients to evaluate the analgesic effect of a 100 µg dose of sublingual fentanyl administered before a colonoscopy. Pain, sedation, nausea, and satisfaction were assessed during the colonoscopy by the patients as well as the endoscopists and nurses. Respiratory rate and peripheral arteriolar oxygen saturation were monitored throughout the procedure. There were no differences between the fentanyl and placebo groups in any of the measured variables. The median pain intensity values, as measured using a numerical rating scale, were 4.5 in the fentanyl group and 5 in the placebo group. The sedation and oxygen saturation levels and the respiratory rate did not differ between the groups. The majority of the colonoscopies were completed.Our results indicate that a 100 µg dose of sublingual fentanyl is not beneficial compared to the placebo in the treatment of procedural pain during a colonoscopy.
Conflict of interest statement
The authors declare no competing interests.
Similar articles
-
Efficacy and safety of sublingual fentanyl orally disintegrating tablet at doses determined by titration for the treatment of breakthrough pain in Japanese cancer patients: a multicenter, randomized, placebo-controlled, double-blind phase III trial.Int J Clin Oncol. 2015 Feb;20(1):198-206. doi: 10.1007/s10147-014-0697-z. Epub 2014 May 20. Int J Clin Oncol. 2015. PMID: 24839047 Clinical Trial.
-
Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain.Curr Med Res Opin. 2009 Dec;25(12):2877-85. doi: 10.1185/03007990903368310. Curr Med Res Opin. 2009. PMID: 19814586 Clinical Trial.
-
Efficacy, safety, and tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain: a randomized, double-blind, placebo-controlled study.Daru. 2021 Jun;29(1):51-59. doi: 10.1007/s40199-020-00381-6. Epub 2021 Jan 21. Daru. 2021. PMID: 33475984 Free PMC article. Clinical Trial.
-
Sufentanil 30 µg Sublingual Tablet: A Review in Acute Pain.Clin Drug Investig. 2019 Apr;39(4):411-418. doi: 10.1007/s40261-019-00772-x. Clin Drug Investig. 2019. PMID: 30887417 Review.
-
Fentanyl buccal tablet.Drugs Today (Barc). 2008 Jan;44(1):41-54. doi: 10.1358/dot.2008.44.1.1178469. Drugs Today (Barc). 2008. PMID: 18301803 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical